{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:29:50Z","timestamp":1791174590487,"version":"4.1.0"},"reference-count":149,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.3892\/ijo.2014.2525","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T13:14:32Z","timestamp":1403788472000},"page":"909-918","source":"Crossref","is-referenced-by-count":20,"title":["Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review)"],"prefix":"10.3892","volume":"45","author":[{"given":"CAMILLA","family":"EVANGELISTI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CECILIA","family":"EVANGELISTI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FRANCESCA","family":"CHIARINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANNALISA","family":"LONETTI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FRANCESCA","family":"BUONTEMPO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIELA","family":"BRESSANIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALESSANDRA","family":"CAPPELLINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ESTER","family":"ORSINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAMES A.","family":"McCUBREY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALBERTO M.","family":"MARTELLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,6,26]]},"reference":[{"key":"key20180107181413_b1-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0272-2712(18)30073-8","article-title":"Acute lymphoblastic leukemia","volume":"20","author":"Farhi","year":"2000","journal-title":"Clin Lab Med"},{"key":"key20180107181413_b2-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1172\/JCI61203","article-title":"Molecular genetics of B-precursor acute lymphoblastic leukemia","volume":"122","author":"Mullighan","year":"2012","journal-title":"J Clin Invest"},{"key":"key20180107181413_b3-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4997\/JRCPE.2012.313","article-title":"The genomics revolution: relevance in healthcare today and tomorrow","volume":"42","author":"Brown","year":"2012","journal-title":"J R Coll Physicians Edinb"},{"key":"key20180107181413_b4-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/leu.2009.223","article-title":"Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways","volume":"24","author":"Zhao","year":"2010","journal-title":"Leukemia"},{"key":"key20180107181413_b5-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/leu.2010.203","article-title":"The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function","volume":"24","author":"Kox","year":"2010","journal-title":"Leukemia"},{"key":"key20180107181413_b6-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"key20180107181413_b7-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.it.2011.06.005","article-title":"Notch in T-ALL: new players in a complex disease","volume":"32","author":"Koch","year":"2011","journal-title":"Trends Immunol"},{"key":"key20180107181413_b8-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.3816\/CLM.2009.s.015","article-title":"T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?","volume":"9","author":"Hoelzer","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"key20180107181413_b9-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/leu.2012.356","article-title":"The role of HOX genes in normal hematopoiesis and acute leukemia","volume":"27","author":"Alharbi","year":"2013","journal-title":"Leukemia"},{"key":"key20180107181413_b10-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11899-012-0122-5","article-title":"Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments","volume":"7","author":"Iacobucci","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"key20180107181413_b11-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/leu.2012.74","article-title":"Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia","volume":"26","author":"Bains","year":"2012","journal-title":"Leukemia"},{"key":"key20180107181413_b12-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/leu.2012.176","article-title":"Impact of NOTCH1\/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial","volume":"27","author":"Jenkinson","year":"2013","journal-title":"Leukemia"},{"key":"key20180107181413_b13-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1038\/leu.2012.116","article-title":"Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency","volume":"26","author":"Blackburn","year":"2012","journal-title":"Leukemia"},{"key":"key20180107181413_b14-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/leu.2012.177","article-title":"Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL","volume":"27","author":"Lhermitte","year":"2013","journal-title":"Leukemia"},{"key":"key20180107181413_b15-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/leu.2012.192","article-title":"Glucocorticoid sensitivity of T-cell lymphoblastic leukemia\/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression","volume":"27","author":"Cialfi","year":"2013","journal-title":"Leukemia"},{"key":"key20180107181413_b16-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/leu.2012.361","article-title":"FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation","volume":"27","author":"Malyukova","year":"2013","journal-title":"Leukemia"},{"key":"key20180107181413_b17-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/leu.2013.63","article-title":"Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia","volume":"27","author":"Correia","year":"2013","journal-title":"Leukemia"},{"key":"key20180107181413_b18-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/leu.2011.273","article-title":"An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-a and cAMP\/PKA pathways","volume":"26","author":"Lv","year":"2012","journal-title":"Leukemia"},{"key":"key20180107181413_b19-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2011.151","article-title":"MicroRNAs in acute leukemia: from biological players to clinical contributors","volume":"26","author":"Schotte","year":"2012","journal-title":"Leukemia"},{"key":"key20180107181413_b20-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2040620712471368","article-title":"The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy","volume":"4","author":"Tosello","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"key20180107181413_b21-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Van Vlierberghe","year":"2012","journal-title":"J Clin Invest"},{"key":"key20180107181413_b22-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/ijc.26318","article-title":"Leukemia stem cells","volume":"129","author":"Buss","year":"2011","journal-title":"Int J Cancer"},{"key":"key20180107181413_b23-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2304","article-title":"The cancer stem cell: premises, promises and challenges","volume":"17","author":"Clevers","year":"2011","journal-title":"Nat Med"},{"key":"key20180107181413_b24-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","article-title":"Evolution of the cancer stem cell model","volume":"14","author":"Kreso","year":"2014","journal-title":"Cell Stem Cell"},{"key":"key20180107181413_b25-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood-2006-06-030445","article-title":"Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia","volume":"109","author":"Cox","year":"2007","journal-title":"Blood"},{"key":"key20180107181413_b26-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1182\/blood-2010-06-292300","article-title":"Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance","volume":"116","author":"Chiu","year":"2010","journal-title":"Blood"},{"key":"key20180107181413_b27-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"e39725","DOI":"10.1371\/journal.pone.0039725","article-title":"NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches","volume":"7","author":"Ma","year":"2012","journal-title":"PloS One"},{"key":"key20180107181413_b28-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/leu.2011.93","article-title":"Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations","volume":"25","author":"Gerby","year":"2011","journal-title":"Leukemia"},{"key":"key20180107181413_b29-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2011.56","article-title":"Intracellular reactive oxygen species are essential for PI3K\/Akt\/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells","volume":"25","author":"Silva","year":"2011","journal-title":"Leukemia"},{"key":"key20180107181413_b30-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107181413_b31-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1517\/17460441.2013.800479","article-title":"Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment","volume":"8","author":"Lv","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"key20180107181413_b32-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"key20180107181413_b33-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/leu.2011.66","article-title":"Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy","volume":"25","author":"Steelman","year":"2011","journal-title":"Leukemia"},{"key":"key20180107181413_b34-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cellsig.2009.01.004","article-title":"Akt-dependent and -independent mechanisms of mTOR regulation in cancer","volume":"21","author":"Memmott","year":"2009","journal-title":"Cell Signal"},{"key":"key20180107181413_b35-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1016\/j.bmcl.2012.06.053","article-title":"Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family","volume":"22","author":"Finlay","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180107181413_b36-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"key20180107181413_b37-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180107181413_b38-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"key20180107181413_b39-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"key":"key20180107181413_b40-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.4161\/cc.26822","article-title":"mTOR\/PRAS40 interaction: hypertrophy or proliferation","volume":"12","author":"Volkers","year":"2013","journal-title":"Cell Cycle"},{"key":"key20180107181413_b41-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2009","journal-title":"J Cell Sci"},{"key":"key20180107181413_b42-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1128\/MCB.24.7.2986-2997.2004","article-title":"A novel mTOR-regulated phosphorylation site in elongation f actor 2 kinase modulates the activity of the kinase and its binding to calmodulin","volume":"24","author":"Browne","year":"2004","journal-title":"Mol Cell Biol"},{"key":"key20180107181413_b43-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"Ma","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180107181413_b44-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","article-title":"Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"key20180107181413_b45-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/leu.2011.46","article-title":"Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K\/PTEN\/Akt\/mTOR pathway","volume":"25","author":"Martelli","year":"2011","journal-title":"Leukemia"},{"key":"key20180107181413_b46-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nature06322","article-title":"mTOR controls mitochondrial oxidative function through a YY1-PGC-1a transcriptional complex","volume":"450","author":"Cunningham","year":"2007","journal-title":"Nature"},{"key":"key20180107181413_b47-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat Med"},{"key":"key20180107181413_b48-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-10-4158","article-title":"Transcriptional control of cellular metabolism by mTOR signaling","volume":"71","author":"Yecies","year":"2011","journal-title":"Cancer Res"},{"key":"key20180107181413_b49-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the pathogenesis of disease","volume":"132","author":"Levine","year":"2008","journal-title":"Cell"},{"key":"key20180107181413_b50-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1091\/mbc.E08-12-1248","article-title":"Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy","volume":"20","author":"Hosokawa","year":"2009","journal-title":"Mol Biol Cell"},{"key":"key20180107181413_b51-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ceb.2009.12.004","article-title":"The role of the Atg1\/ULK1 complex in autophagy regulation","volume":"22","author":"Mizushima","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"key20180107181413_b52-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/blood-2006-06-030833","article-title":"Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML","volume":"109","author":"Zeng","year":"2007","journal-title":"Blood"},{"key":"key20180107181413_b53-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"key20180107181413_b54-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/BJ20081668","article-title":"mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)","volume":"416","author":"Garcia-Martinez","year":"2008","journal-title":"Biochem J"},{"key":"key20180107181413_b55-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/emboj.2008.119","article-title":"Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling","volume":"27","author":"Ikenoue","year":"2008","journal-title":"EMBO J"},{"key":"key20180107181413_b56-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4161\/cc.10.14.16586","article-title":"mTOR complex 2 signaling and functions","volume":"10","author":"Oh","year":"2011","journal-title":"Cell Cycle"},{"key":"key20180107181413_b57-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.4161\/cc.8.23.10091","article-title":"Targeting translation in acute myeloid leukemia: a new paradigm for therapy?","volume":"8","author":"Tamburini","year":"2009","journal-title":"Cell Cycle"},{"key":"key20180107181413_b58-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cub.2004.08.026","article-title":"Inappropriate activation of the TSC\/Rheb\/mTOR\/S6K cassette induces IRS1\/2 depletion, insulin resistance, and cell survival deficiencies","volume":"14","author":"Shah","year":"2004","journal-title":"Curr Biol"},{"key":"key20180107181413_b59-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","article-title":"The two TORCs and Akt","volume":"12","author":"Bhaskar","year":"2007","journal-title":"Dev Cell"},{"key":"key20180107181413_b60-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.bbamcr.2010.01.009","article-title":"Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells","volume":"1803","author":"Lang","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"key20180107181413_b61-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.molcel.2008.03.009","article-title":"The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation","volume":"30","author":"Xu","year":"2008","journal-title":"Mol Cell"},{"key":"key20180107181413_b62-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1083\/jcb.200406136","article-title":"XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum","volume":"167","author":"Sriburi","year":"2004","journal-title":"J Cell Biol"},{"key":"key20180107181413_b63-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1541-7786.MCR-09-0409","article-title":"Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2","volume":"8","author":"Boulbes","year":"2010","journal-title":"Mol Cancer Res"},{"key":"key20180107181413_b64-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"13375","DOI":"10.1074\/jbc.273.22.13375","article-title":"The tumor suppressor, PTEN\/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate","volume":"273","author":"Maehama","year":"1998","journal-title":"J Biol Chem"},{"key":"key20180107181413_b65-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2004.02.141","article-title":"The biology and clinical relevance of the PTEN tumor suppressor pathway","volume":"22","author":"Sansal","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180107181413_b66-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10254-003-0016-y","article-title":"The role of SHIP in cytokine-induced signaling","volume":"149","author":"Kalesnikoff","year":"2003","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"key20180107181413_b67-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1101\/gad.13.7.786","article-title":"SHIP is a negative regulator of growth factor receptor-mediated PKB\/Akt activation and myeloid cell survival","volume":"13","author":"Liu","year":"1999","journal-title":"Genes Dev"},{"key":"key20180107181413_b68-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc2842","article-title":"Phosphoinositide signalling in cancer: beyond PI3K and PTEN","volume":"10","author":"Bunney","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20180107181413_b69-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2013.02.036","article-title":"Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer","volume":"335","author":"Seshacharyulu","year":"2013","journal-title":"Cancer Lett"},{"key":"key20180107181413_b70-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature06933","article-title":"Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation","volume":"453","author":"Guo","year":"2008","journal-title":"Nature"},{"key":"key20180107181413_b71-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1073\/pnas.1006937108","article-title":"Suppression of leukemia development caused by PTEN loss","volume":"108","author":"Guo","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107181413_b72-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.1320265111","article-title":"Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells","volume":"111","author":"Hoshii","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107181413_b73-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1236566","DOI":"10.1126\/science.1236566","article-title":"mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin","volume":"341","author":"Kang","year":"2013","journal-title":"Science"},{"key":"key20180107181413_b74-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/0008-5472.CAN-08-4884","article-title":"Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia","volume":"69","author":"Chiarini","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107181413_b75-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/leu.2011.20","article-title":"Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia","volume":"25","author":"Evangelisti","year":"2011","journal-title":"Leukemia"},{"key":"key20180107181413_b76-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"811","DOI":"10.18632\/oncotarget.579","article-title":"Harnessing the PI3K\/Akt\/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels","volume":"3","author":"Bressanin","year":"2012","journal-title":"Oncotarget"},{"key":"key20180107181413_b77-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.stem.2012.05.026","article-title":"Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression","volume":"11","author":"Magee","year":"2012","journal-title":"Cell Stem Cell"},{"key":"key20180107181413_b78-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.beha.2011.09.004","article-title":"Genomic profiling of B-progenitor acute lymphoblastic leukemia","volume":"24","author":"Mullighan","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"key20180107181413_b79-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"key20180107181413_b80-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/leu.2009.209","article-title":"Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia","volume":"24","author":"Jotta","year":"2010","journal-title":"Leukemia"},{"key":"key20180107181413_b81-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/gcc.20684","article-title":"Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome","volume":"48","author":"Karrman","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"key20180107181413_b82-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"371","DOI":"10.18632\/oncotarget.477","article-title":"Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment","volume":"3","author":"Martelli","year":"2012","journal-title":"Oncotarget"},{"key":"key20180107181413_b83-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"e59335","DOI":"10.1371\/journal.pone.0059335","article-title":"Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL)","volume":"8","author":"Nemes","year":"2013","journal-title":"PLoS One"},{"key":"key20180107181413_b84-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","article-title":"High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia","volume":"114","author":"Gutierrez","year":"2009","journal-title":"Blood"},{"key":"key20180107181413_b85-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3324\/haematol.2012.073585","article-title":"NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia","volume":"98","author":"Bandapalli","year":"2013","journal-title":"Haematologica"},{"key":"key20180107181413_b86-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","article-title":"Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study","volume":"31","author":"Trinquand","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107181413_b87-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/gcc.22039","article-title":"The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL","volume":"52","author":"Grossmann","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"key20180107181413_b88-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1636","article-title":"Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia","volume":"13","author":"Palomero","year":"2007","journal-title":"Nat Med"},{"key":"key20180107181413_b89-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"18261","DOI":"10.1073\/pnas.0606108103","article-title":"NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth","volume":"103","author":"Palomero","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107181413_b90-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1084\/jem.20101691","article-title":"Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia","volume":"208","author":"Gutierrez","year":"2011","journal-title":"J Exp Med"},{"key":"key20180107181413_b91-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/ncb2037","article-title":"Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia","volume":"12","author":"Mavrakis","year":"2010","journal-title":"Nat Cell Biol"},{"key":"key20180107181413_b92-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1172\/JCI34616","article-title":"PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability","volume":"118","author":"Silva","year":"2008","journal-title":"J Clin Invest"},{"key":"key20180107181413_b93-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"22836","DOI":"10.1074\/jbc.M113.451625","article-title":"Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells","volume":"288","author":"Hales","year":"2013","journal-title":"J Biol Chem"},{"key":"key20180107181413_b94-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1084\/jem.20110121","article-title":"High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling","volume":"208","author":"Medyouf","year":"2011","journal-title":"J Exp Med"},{"key":"key20180107181413_b95-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/leu.2008.178","article-title":"Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling","volume":"23","author":"Cardoso","year":"2009","journal-title":"Leukemia"},{"key":"key20180107181413_b96-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1084\/jem.20040789","article-title":"Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells","volume":"200","author":"Barata","year":"2004","journal-title":"J Exp Med"},{"key":"key20180107181413_b97-ijo-45-03-0909","first-page":"1229","article-title":"Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7","volume":"88","author":"Scupoli","year":"2003","journal-title":"Haematologica"},{"key":"key20180107181413_b98-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat Genet"},{"key":"key20180107181413_b99-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"7975","DOI":"10.1158\/1078-0432.CCR-07-4846","article-title":"Translating an antagonist of chemokine receptor CXCR4: from bench to bedside","volume":"14","author":"Wong","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20180107181413_b100-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.12098","article-title":"Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12\/CXCR4 axis and the NF-\u03baB and JNK\/AP-1 pathways","volume":"93","author":"Scupoli","year":"2008","journal-title":"Haematologica"},{"key":"key20180107181413_b101-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood-2010-01-262691","article-title":"Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers","volume":"117","author":"Pillozzi","year":"2011","journal-title":"Blood"},{"key":"key20180107181413_b102-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"key":"key20180107181413_b103-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/187152010793498663","article-title":"Updates of mTOR inhibitors","volume":"10","author":"Zhou","year":"2010","journal-title":"Anticancer Agents Med Chem"},{"key":"key20180107181413_b104-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"key20180107181413_b105-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood-2005-03-0929","article-title":"Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells","volume":"106","author":"Avellino","year":"2005","journal-title":"Blood"},{"key":"key20180107181413_b106-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2006-08-039883","article-title":"Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia","volume":"110","author":"Chan","year":"2007","journal-title":"Blood"},{"key":"key20180107181413_b107-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3109\/10428194.2013.811579","article-title":"Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt\/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways","volume":"55","author":"Wu","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"key20180107181413_b108-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.leukres.2010.12.028","article-title":"Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin","volume":"35","author":"Akers","year":"2011","journal-title":"Leukemia Res"},{"key":"key20180107181413_b109-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"457e453","DOI":"10.1016\/j.exphem.2011.01.005","article-title":"Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors","volume":"39","author":"Batista","year":"2011","journal-title":"Exp Hematol"},{"key":"key20180107181413_b110-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/pbc.21296","article-title":"Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"key20180107181413_b111-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","article-title":"Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies","volume":"12","author":"Yee","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20180107181413_b112-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20180107181413_b113-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2008-10-184515","article-title":"Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia","volume":"114","author":"Tamburini","year":"2009","journal-title":"Blood"},{"key":"key20180107181413_b114-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1158\/0008-5472.CAN-10-1814","article-title":"Activity of the novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia","volume":"70","author":"Chiarini","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107181413_b115-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1084\/jem.20042020","article-title":"The Pim kinases control rapamycin-resistant T cell survival and activation","volume":"201","author":"Fox","year":"2005","journal-title":"J Exp Med"},{"key":"key20180107181413_b116-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.8.9.8210","article-title":"PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells","volume":"8","author":"Zhang","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"key20180107181413_b117-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood-2009-07-233445","article-title":"A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia\/lymphoma","volume":"115","author":"Lin","year":"2010","journal-title":"Blood"},{"key":"key20180107181413_b118-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2007-03-080796","article-title":"Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase\/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways","volume":"111","author":"Tamburini","year":"2008","journal-title":"Blood"},{"key":"key20180107181413_b119-ijo-45-03-0909","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"key20180107181413_b120-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"key20180107181413_b121-ijo-45-03-0909","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2014.123","article-title":"Feedbacks and adaptive capabilities of the PI3K\/Akt\/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis","author":"Bertacchini","year":"2014","journal-title":"Leukemia"},{"key":"key20180107181413_b122-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/leu.2013.17","article-title":"A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse","volume":"27","author":"Park","year":"2013","journal-title":"Leukemia"},{"key":"key20180107181413_b123-ijo-45-03-0909","article-title":"A phase I\/II study of hyper-CVAD plus everolimus in patients with relapsed\/refractory acute lymphoblastic leukemia","volume-title":"Blood","author":"Daver","year":"2013"},{"key":"key20180107181413_b124-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccr.2006.03.029","article-title":"A dual PI3 kinase\/mTOR inhibitor reveals emergent efficacy in glioma","volume":"9","author":"Fan","year":"2006","journal-title":"Cancer Cell"},{"key":"key20180107181413_b125-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","article-title":"The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma","volume":"16","author":"Cho","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180107181413_b126-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.4161\/cbt.21144","article-title":"Dual PI3K\/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1\u03b1 expression by blocking protein translation and increases cell death under hypoxia","volume":"13","author":"Karar","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"key20180107181413_b127-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.2174\/092986711796391651","article-title":"ATP-competitive inhibitors of mTOR: an update","volume":"18","author":"Schenone","year":"2011","journal-title":"Curr Med Chem"},{"key":"key20180107181413_b128-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/leu.2012.285","article-title":"PI3K\/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response","volume":"27","author":"Shepherd","year":"2013","journal-title":"Leukemia"},{"key":"key20180107181413_b129-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1158\/0008-5472.CAN-06-4615","article-title":"Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases","volume":"67","author":"Raynaud","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107181413_b130-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"key20180107181413_b131-ijo-45-03-0909","first-page":"463","article-title":"The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells","volume":"32","author":"Schult","year":"2012","journal-title":"Anticancer Res"},{"key":"key20180107181413_b132-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood-2012-08-446096","article-title":"Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas","volume":"121","author":"Shortt","year":"2013","journal-title":"Blood"},{"key":"key20180107181413_b133-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.23761","article-title":"Chemotherapy induced DNA damage response: convergence of drugs and pathways","volume":"14","author":"Woods","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"key20180107181413_b134-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-12-46","article-title":"Cell cycle-dependent activity of the novel dual PI3K-mTORC1\/2 inhibitor NVP-BGT226 in acute leukemia","volume":"12","author":"Kampa-Schittenhelm","year":"2013","journal-title":"Mol Cancer"},{"key":"key20180107181413_b135-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/annonc\/mdr137","article-title":"Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors","volume":"23","author":"Soria","year":"2012","journal-title":"Ann Oncol"},{"key":"key20180107181413_b136-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"key":"key20180107181413_b137-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/onc.2008.246","article-title":"Drug discovery approaches targeting the PI3K\/Akt pathway in cancer","volume":"27","author":"Garcia-Echeverria","year":"2008","journal-title":"Oncogene"},{"key":"key20180107181413_b138-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1016\/j.bmcl.2010.05.099","article-title":"Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment","volume":"20","author":"Garcia-Echeverria","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"key20180107181413_b139-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/14728222.2012.677439","article-title":"An overview of the mTOR pathway as a target in cancer therapy","volume":"16","author":"Gentzler","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"key20180107181413_b140-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1158\/1078-0432.CCR-10-2285","article-title":"Dual mTORC2\/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors","volume":"17","author":"Altman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107181413_b141-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/leu.2011.339","article-title":"The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia","volume":"26","author":"Willems","year":"2012","journal-title":"Leukemia"},{"key":"key20180107181413_b142-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood-2011-04-346601","article-title":"Dual mTORC1\/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"key20180107181413_b143-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"key20180107181413_b144-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2012.276","article-title":"Efficacy of the investigational mTOR kinase inhibitor MLN0128\/INK128 in models of B-cell acute lymphoblastic leukemia","volume":"27","author":"Janes","year":"2013","journal-title":"Leukemia"},{"key":"key20180107181413_b145-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"156","DOI":"10.18632\/oncotarget.119","article-title":"Role of Pten in leukemia stem cells","volume":"1","author":"Peng","year":"2010","journal-title":"Oncotarget"},{"key":"key20180107181413_b146-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature04703","article-title":"Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells","volume":"441","author":"Yilmaz","year":"2006","journal-title":"Nature"},{"key":"key20180107181413_b147-ijo-45-03-0909","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","author":"Kaplan","year":"2014","journal-title":"Transplant Rev"},{"key":"key20180107181413_b148-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mds011","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors","volume":"23","author":"Markman","year":"2012","journal-title":"Ann Oncol"},{"key":"key20180107181413_b149-ijo-45-03-0909","doi-asserted-by":"crossref","first-page":"e88865","DOI":"10.1371\/journal.pone.0088865","article-title":"Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1","volume":"9","author":"Mallya","year":"2014","journal-title":"PloS One"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2014.2525\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T23:18:01Z","timestamp":1565565481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2014.2525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,26]]},"references-count":149,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,6,26]]},"published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.3892\/ijo.2014.2525"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2014.2525","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,26]]}}}